Neumann, F.; Rose, R.; Römpke, J.; Grobe, O.; Lorentz, T.; Fickenscher, H.; Krumbholz, A.
Development of SARS-CoV-2 Specific IgG and Virus-Neutralizing Antibodies after Infection with Variants of Concern or Vaccination. Vaccines 2021, 9, 700.
https://doi.org/10.3390/vaccines9070700
AMA Style
Neumann F, Rose R, Römpke J, Grobe O, Lorentz T, Fickenscher H, Krumbholz A.
Development of SARS-CoV-2 Specific IgG and Virus-Neutralizing Antibodies after Infection with Variants of Concern or Vaccination. Vaccines. 2021; 9(7):700.
https://doi.org/10.3390/vaccines9070700
Chicago/Turabian Style
Neumann, Franziska, Ruben Rose, Janine Römpke, Olaf Grobe, Thomas Lorentz, Helmut Fickenscher, and Andi Krumbholz.
2021. "Development of SARS-CoV-2 Specific IgG and Virus-Neutralizing Antibodies after Infection with Variants of Concern or Vaccination" Vaccines 9, no. 7: 700.
https://doi.org/10.3390/vaccines9070700
APA Style
Neumann, F., Rose, R., Römpke, J., Grobe, O., Lorentz, T., Fickenscher, H., & Krumbholz, A.
(2021). Development of SARS-CoV-2 Specific IgG and Virus-Neutralizing Antibodies after Infection with Variants of Concern or Vaccination. Vaccines, 9(7), 700.
https://doi.org/10.3390/vaccines9070700